Kura Oncology, Inc. filings document a Nasdaq-listed biopharmaceutical company focused on precision medicines for cancer, including disclosures on KOMZIFTI™ (ziftomenib), acute myeloid leukemia programs, darlifarnib (KO-2806) and collaboration activity with Kyowa Kirin. Form 8-K reports cover financial results, FDA approval and product-launch disclosures, clinical program updates, milestone payments and other material events.
Governance filings include the company’s definitive proxy statement for annual meeting matters, director elections, auditor ratification and executive compensation. Other filings describe amendments to bylaws, the 2023 Inducement Option Plan, nonstatutory stock option grants and the company’s common stock listing on The Nasdaq Global Select Market.
Kura Oncology, Inc. (KURA) reported that its Chief Financial Officer, Jennifer Fulk, has filed an initial statement of beneficial ownership of securities on Form 3. The submission lists no reportable transactions, acquisitions, or dispositions of Kura Oncology securities and shows no derivative positions.
Kura Oncology, Inc. (symbol: KURA) is the issuer of record for a Form 8-K filing submitted to the SEC.
Kura Oncology, Inc. (KURA) appointed Jennifer Fulk as Chief Financial Officer, principal financial officer and principal accounting officer effective September 8, 2026, replacing Troy E. Wilson, Ph.D., J.D. and Thomas Doyle in those specific roles. Fulk brings prior CFO and operating experience at Soleno Therapeutics, 120Water, Talkspace and Eli Lilly and Company.
Under her September 8, 2026 employment agreement, Fulk receives a $550,000 annual base salary, is eligible for an annual discretionary bonus of up to 45% of base salary, an option to purchase 450,000 shares of common stock and a one-time performance-based restricted stock unit award covering 173,438 shares. The option vests over four years and the PSUs vest in six installments based on revenue, clinical and regulatory milestones.
The agreement provides cash severance, COBRA premium payments, option exercise extensions and, in a qualifying termination in connection with a Corporate Transaction, additional cash, extended COBRA coverage and full acceleration of all outstanding equity awards, with performance-based awards vesting at target.
Kura Oncology, Inc. (KURA) disclosed that President and CEO Troy Edward Wilson, through the One Fish Two Fish Revocable Trust, purchased 100,000 shares of common stock on 2026-08-24 at a weighted average price of $12.39 per share, from individual trades between $11.47 and $12.85. Following this purchase, that trust held 479,194 shares indirectly, in addition to 300,000 shares held indirectly by the Lorax Charitable Remainder Unitrust and 435,456 shares held directly.
Kura Oncology, Inc. (KURA) reported that Chief Commercial Officer Brian T. Powl sold 4,345 shares of common stock on August 21, 2026 at a weighted average price of $11.8903 per share. After this 10b5-1 plan trade, he held 169,269 shares of Kura Oncology common stock directly.
Kura Oncology, Inc. (KURA) had an affiliate, Brian T. Powl, file a notice of proposed sale of company stock under Rule 144. The notice covers the potential sale of 4,345 shares of common stock through Morgan Stanley Smith Barney LLC, with an indicated value of approximately $50,879.95.
The shares were acquired upon the vesting of restricted stock units during the period from 01/26/2025 through 01/26/2026. The notice lists NASDAQ as the trading market and is dated 08/21/2026.
Kura Oncology, Inc. (KURA) reported that Chief Legal Officer Teresa Brophy Bair sold 31,487 shares of common stock on August 19, 2026 in an open-market transaction at a weighted average price of $12.63 per share, with trade prices ranging from $12.44 to $12.83. These shares had been acquired upon vesting of restricted stock units between January 26, 2024 and January 26, 2026. After this sale, she directly holds 195,444 shares of Kura Oncology common stock. The sale was effected under a Rule 10b5-1 trading plan adopted on May 20, 2026.
Kura Oncology, Inc. (KURA) is named as the issuer in a planned resale of its common stock under Rule 144. Officer Teresa Bair filed notice to sell 31,487 shares of Kura common stock through Morgan Stanley Smith Barney LLC. The proposed sale is referenced with a date of 08/19/2026 on the NASDAQ market. The shares were acquired upon vesting of restricted stock units during the period from 01/26/2024 through 01/26/2026.
Kura Oncology, Inc. director and President and CEO Troy Edward Wilson reported a purchase of 100,000 shares of Common Stock on 2026-08-17 at a weighted average price of $11.12 per share, executed in multiple trades between $10.87 and $11.31. The purchased shares are held indirectly by One Fish Two Fish Revocable Trust, bringing that trust’s reported holdings to 379,194 shares following the transaction. Additional reported positions include 300,000 shares held indirectly by Lorax Charitable Remainder Unitrust and 435,456 shares held directly by the reporting person.
Montanova Capital, LLC, Averill Master Fund, Ltd., and Aaron Cowen report significant ownership stakes in Kura Oncology, Inc. common stock. Montanova Capital and Aaron Cowen each report beneficial ownership of 8,575,422 shares of common stock, representing 9.7% of the class. Averill Master Fund reports beneficial ownership of 7,805,540 shares, representing 8.8% of the class.
All of the securities reported in this Amendment No. 6 are directly owned by advisory clients of Montanova Capital, LLC, with Averill Master Fund, Ltd. being the only client that may be deemed to beneficially own more than 5% of the common stock. Each reporting person disclaims beneficial ownership except to the extent of their pecuniary interest.